Theravance Biopharma (NASDAQ:TBPH) Earns News Impact Score of 0.14

Media coverage about Theravance Biopharma (NASDAQ:TBPH) has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Theravance Biopharma earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.5732768152639 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several equities research analysts have recently commented on the stock. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday. Piper Jaffray reissued an “overweight” rating and set a $45.00 price target on shares of Theravance Biopharma in a research report on Thursday, March 29th. BidaskClub raised shares of Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Friday, February 9th. Leerink Swann lifted their price target on shares of Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Finally, Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the company a “buy” rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $42.43.

How to Become a New Pot Stock Millionaire

Shares of TBPH stock traded down $1.00 during trading hours on Friday, reaching $23.23. The company had a trading volume of 153,463 shares, compared to its average volume of 268,237. The company has a quick ratio of 5.79, a current ratio of 6.05 and a debt-to-equity ratio of 1.94. The firm has a market capitalization of $1,327.74, a PE ratio of -4.26 and a beta of 1.81. Theravance Biopharma has a one year low of $22.90 and a one year high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.49). The business had revenue of $4.52 million for the quarter, compared to the consensus estimate of $3.71 million. Theravance Biopharma had a negative net margin of 1,855.42% and a negative return on equity of 136.86%. analysts anticipate that Theravance Biopharma will post -4.61 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Theravance Biopharma (NASDAQ:TBPH) Earns News Impact Score of 0.14” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Insider Buying and Selling by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with's FREE daily email newsletter.

Leave a Reply